NCT04856761招募中不适用
A Phase II, Open-Label Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- RFS, recurrence-free survival
研究概览
简要总结
The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery.
详细描述
Patients received curative BTC surgery will be informed about the study. After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be observed for recurrence of BTC.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age> 18 years old, and <75 years old.
- •Diagnosis is gallbladder cancer or biliary adenocarcinoma via pathological histology.
- •Patients have received curative surgery of gallbladder cancer or bile duct cancer, and postoperative pathology has confirmed R0 / R1 resection.
- •Ability to comply with the study protocol, in the investigator's judgment.
- •No tumor recurrence before the start of chemotherapy.
- •No fluorouracil drugs were used in the past six months.
- •The main organ function is good, that is, within 14 days before the start of medication, laboratory inspection confirmed that there is sufficient bone marrow function, liver function, renal function, heart function: hemoglobin ≥90g / L; neutral granulocyte count ≥1.5 × 109 / L; platelet ≥ 70 × 109 / L; alt, AST ≤ 3 × ULN (normal value upper limit); total bilirubin ≤ 2.5 × ULN (normal value upper limit)); serum creatinine <1.5 × ULN (normal value upper limit); Serum albumin ≥ 30g / L; coagulation function: PT extended <2s.
- •ECOG score <
- •Signed Informed Consent Form.
- •Male and female subjects with potential fertility must agree to adopt high-efficiency contraceptive methods during the study of at least 3 months after receiving the last treatment.
排除标准
- •First chemotherapy start time > 16 postoperatively weeks.
- •Patients with other tumors, or patients with recurrence before chemotherapy;
- •History of allergic with study drugs;
- •History of organ transplantation requires immunosuppressive treatment;
- •Pregnancy or lactation women;
- •Accept the following system treatment within 4 weeks before the start of treatment: cytotoxic treatment, signal conduction inhibitors, immunotherapy, hormone therapy.
- •Participate in other clinical trials within 3 months;
- •Abnormality of the peripheral nervous system (> NCI CTC 1), clinically significant mental abnormalities, have a history of abnormal history of the central nervous system;
- •Electrocardiogram abnormal or clinically obvious heart disease, such as: congestive heart failure, symptomatic coronary heart disease, arrhythmia, clinical manifestations of heart disease, or epasus in the past 12 months; severe infection (> GRADE 2 National Cancer Institute [NCI] -Common Terminology Criteria for AdverSe Events [CTCAE] Version 3.0), sepsis, severe metabolism or diabetes; Digestive ulcer activity period requires treatment, absorption disabilities, diarrhea, intestinal obstruction , Destroyer of the upper deactivated tract integrity;
- •History of HIV infection;
- •Anti-viral treatment cannot be controlled or chronic hepatitis C;
- •Renal failure requires blood or peritoneal dialysis;
- •There are some other serious or unstable diseases or medical, social, sychological states, can endanger the safety of the subject and / or his / her to study the compliance or can prevent patients to participate in clinical research or The assessment of the research results;
- •Refused follow-up in accordance with the requirements set by this research program, as well as refused to sign informed consent.
- •Other factors that may affect patient income and assessment results;
研究组 & 干预措施
S-1 Group
In this group, S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
干预措施: S-1 (Drug)
Cape Group
In this group, capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
干预措施: Capecitabine (Drug)
结局指标
主要结局
RFS, recurrence-free survival
时间窗: Enrollment to 1 year
RFS was counted from the enrollment to the date on which disease progression or death was detected, or was censored on the last date when progression-free status was confirmed.
次要结局
- OS, overall survival(Enrollment to 3 years)
研究者
Lunxiu Qin
Director, Department of Surgery, Huashan Hospital
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal CancerRectal CancerNCT01043484Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)90
已完成
2 期
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast CancerBreast CancerNCT02846428Hoffmann-La Roche182
Unknown
2 期
Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)Potentially Resectable Liver Metastasis From CRCColorectal CancerNCT00997685Guangdong Provincial People's Hospital110
Unknown
2 期
Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast CancerMetastasisBreast CancerNCT01196455Croatian Cooperative Group for Clinical Research in Oncology39
已完成
2 期
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell CarcinomaKidney CancerRenal Cell CarcinomaNCT00496587M.D. Anderson Cancer Center34